Ingredients · Hype vs Evidence
PDRN Is Everywhere. But Does the Science Match the Hype?
Salmon-DNA serums and injections are the skincare story of the moment. The best evidence is real, but it mostly concerns injected products and wound healing, not the serum on your shelf.
Key takeaway: The evidence for PDRN and polynucleotides is genuinely promising, but it rests on a small number of trials of injected or clinician-applied products. Shop-bought serums are a different product, and the evidence answers that question much less well.
What PDRN is
PDRN stands for polydeoxyribonucleotide: a mixture of DNA fragments, usually extracted from the reproductive tissue of salmon or trout. Much of the research began in wound healing. It has since moved into aesthetics as an injected 'skin booster' and into consumer skincare as serums, creams and masks. A closely related term, polynucleotides (PN), describes highly purified DNA-derived polymers used in similar injectable treatments.
Why it could work
In laboratory and animal studies, PDRN has been shown to encourage the growth and movement of skin cells, support new blood-vessel formation and dampen inflammation. One leading idea is that it acts on the adenosine A2A receptor and supplies nucleotides that damaged cells can reuse. Those are plausible mechanisms, and they are only that. A mechanism does not show that a product visibly improves ageing skin.
What human studies show
The most useful recent synthesis is a 2026 systematic review of randomised trials of polynucleotide and PDRN treatments. It found seven trials with 183 participants in total: four on skin rejuvenation, one on preventing scars after surgery and two on wound healing. Across them, treated groups improved on wrinkle-related measures, scar quality, healing measures and patient satisfaction. The most consistent benefit was in wound healing, where PDRN sped up re-epithelialisation and shortened healing time compared with controls. No serious treatment-related adverse events were reported.
Read those numbers with care. Seven trials and 183 people is a small evidence base. Protocols and outcome measures differ from trial to trial, and the review's authors call for larger, adequately powered studies before firm conclusions are drawn.
Injectable is not the same as topical
Almost all of this research concerns products injected into the skin or applied by clinicians. A serum you use at home is a different product in a different form. One cosmetic chemist quoted by NBC News Select put typical topical levels at roughly 0.5% to 1.5%. Whether DNA fragments of this kind reach the living layers of intact skin in meaningful amounts from a cream is not something the trials above answer. Hydration and barrier support are plausible surface benefits, but injectable evidence should not be borrowed to sell a serum.
Safety and regulation
In the trials reviewed, no serious treatment-related adverse events were reported, but the samples are small, and any injection carries procedure risks such as bruising, infection or poor technique. Regulation varies by country and by product. At the time of writing, no injectable PN or PDRN product is approved by the US FDA for use in the skin, so clinics offering them there are working outside approval. Topical PDRN is sold as a cosmetic, which means it cannot legally make medical claims. If you are considering an injection anywhere, ask which exact product is used, how it is classified in that country and who will administer it.
The LCY verdict
Trend: rising. PDRN is showing up in mainstream health and beauty coverage and in a growing number of reviews, which is why it is on our radar. We have not quantified search or social volume, so this is an editorial call, not a score.
Evidence: C (Emerging) for injectable and clinician-applied use, D (Weak) for topical cosmetic products. The signal is real, but it is narrower than the marketing suggests.
The evidence box
| THE LCY EVIDENCE BOX | Our assessment |
|---|---|
| THE CLAIM | PDRN and polynucleotides rejuvenate skin and help tissue heal, and PDRN serums deliver similar results. |
| WHY IT COULD WORK | Laboratory and animal studies show effects on cell growth, blood-vessel formation and inflammation, possibly through adenosine A2A signalling. This is mechanism, not proof of clinical benefit. |
| WHAT HUMAN STUDIES SHOW | A 2026 systematic review found seven randomised trials (183 participants) with improvements in wrinkle measures, scar quality and wound healing, most consistently in wound healing. Data on shop-bought serums are far thinner. |
| QUALITY OF EVIDENCE | Small samples, differing protocols and outcome measures, and few trials. |
| CLINICAL SIGNIFICANCE | The wound-healing benefit looks meaningful. The size and durability of any aesthetic benefit are not established. |
| SAFETY | No serious treatment-related adverse events in the trials reviewed. Injections carry procedure risks. |
| REGULATORY STATUS | No injectable PN or PDRN product is FDA-approved for intradermal skin use in the US. Status elsewhere varies by product. Topical PDRN is a cosmetic. |
| WHO FUNDED THE STUDY / CONFLICTS | We have not verified funding for each trial in the review. Where a trial tests a branded product, check who paid for it. |
| LCY EVIDENCE METER | C (Emerging) for injectable and clinician-applied use. D (Weak) for topical cosmetic PDRN. |
| WHAT WE STILL DON'T KNOW | Best products, doses and schedules; long-term results; whether topical PDRN does anything measurable beyond moisturising; how it compares with established treatments. |
What we know
Randomised trials of PN and PDRN report favourable results, most consistently for wound healing.
The best data concern injected or clinician-applied products.
No serious treatment-related adverse events were reported in the trials reviewed.
What we don't know
Whether topical serums deliver meaningful effects beyond moisturising.
How long benefits last, and how products compare with each other and with established treatments.
Which doses and schedules work best.
Sources
The impact of polydeoxyribonucleotide on wound healing: a systematic review (opens in a new tab) (International Surgery Journal, 2025)
Polydeoxyribonucleotide in the Treatment of Tendon Disorders, from Basic Science to Clinical Practice: A Systematic Review (opens in a new tab) (mechanism background)
NBC News Select explainer on PDRN skincare (opens in a new tab) (topical levels and US regulatory status)
Editorial evidence review. This article was prepared from the sources listed above and has not yet been reviewed by a named medical or cosmetic-science expert. It is general information, not medical advice. Images are illustrative and generated with AI.
